GS-9451

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2012-2016
012320122016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2017
Review
2017
INTRODUCTION Hepatitis C Virus (HCV) is a chronic infection of the liver and the leading cause of liver failure and liver… (More)
Is this relevant?
2016
2016
BACKGROUND As treatment for chronic hepatitis C (HCV) virus has evolved to all-oral, interferon-free directly acting antiviral… (More)
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 4
Is this relevant?
2016
2016
BACKGROUND Treatment of genotype 1 hepatitis C virus (HCV) infection with combination directly acting antivirals (DAA) for 8-24… (More)
  • table 1
  • table 2
  • table 3
Is this relevant?
2016
2016
The hepatitis C virus (HCV), of the family flaviviridae, is one of the major causes of chronic liver diseases. Until the year… (More)
Is this relevant?
2015
2015
BACKGROUND Hepatitis C virus (HCV) RNA loads serve as predictors of treatment response during interferon-based therapy. We… (More)
  • table 1
  • table 2
  • figure 3
Is this relevant?
2014
2014
GS-9451 is a selective hepatitis C virus (HCV) NS3 protease inhibitor in development for the treatment of genotype 1 (GT1) HCV… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
2013
2013
BACKGROUND GS-9451 is a novel inhibitor of the HCV NS3/4A protease and demonstrates potent in vitro suppression of HCV genotype 1… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
2012
2012
The discovery of GS-9451 is reported. Modification of the P3 cap and P2 quinoline with a series of solubilizing groups led to the… (More)
  • figure 1
  • table 1
  • table 2
  • table 4
  • figure 2
Is this relevant?
2012
2012
GS-9451, a novel hepatitis C virus (HCV) nonstructural 3/4a (NS3/4a) protease inhibitor, is highly active in patients infected… (More)
  • table 2
  • table 3
  • figure 2
Is this relevant?
2012
2012
The high genetic variation of hepatitis C virus (HCV) results in rapid selection of drug resistance mutations (DRMs) during… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • figure 2
Is this relevant?